Physician profile
Paul D Jackson
NPI 1053391342
$11,119.71
in general payments reported to CMS, 2019-2025
54 companies · $1,858 in 2025
The $1,858 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,522 · 2020: $962 · 2021: $1,537 · 2022: $1,859 · 2023: $1,625 · 2024: $1,757 · 2025: $1,858.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,239.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,713.73 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,190.91 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $1,187.53 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $919.85 | 2019-2025 | Jardiance, Glyxambi, Tradjenta |
| Abbvie INC. | $667.33 | 2021-2025 | |
| Glaxosmithkline, LLC. | $487.26 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $479.28 | 2019-2023 | Xarelto |
| Pfizer INC. | $461.59 | 2019-2025 | |
| Amgen INC. | $383.43 | 2019-2025 | Otezla, Repatha, Repatha |
| Merck Sharp & Dohme LLC | $372.35 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Sanofi-Aventis U.S. LLC | $343.08 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $322.07 | 2021-2024 | |
| Astellas Pharma US INC | $224.57 | 2019-2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $201.02 | 2023-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $185.94 | 2019-2025 | Austedo Xr, Ajovy |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.